Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 16/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | HTR2A | P28223 | 3/20 | 0.53 |
| ▸ | HTR7 | P34969 | 2/20 | 0.52 |
| ▸ | DRD2 | P14416 | 2/20 | 0.52 |
| ▸ | PPARG | P37231 | 2/20 | 0.50 |
| ▸ | PPARD | Q03181 | 2/20 | 0.50 |
| ▸ | PPARA | Q07869 | 2/20 | 0.50 |
| ▸ | HTR1A | P08908 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13302272 | 0.92 | HTR6 (0.62) | HTR6L3MBTL1HTR2AHTR7DRD2 | |
| SCHEMBL13302287 | 0.89 | HTR6 (0.48) | HTR6L3MBTL1HTR2AHTR7DRD2 | |
| SCHEMBL13323649 | 0.89 | HTR6 (0.51) | HTR6L3MBTL1HTR2AHTR7DRD2 | |
| SCHEMBL13302171 | 0.87 | L3MBTL1 (0.59) | HTR6L3MBTL1HTR2APTGS2 | |
| SCHEMBL3336570 | 0.82 | L3MBTL1 (0.47) | HTR6L3MBTL1HTR2AHTR7DRD2 | |
| SCHEMBL28984412 | 0.81 | L3MBTL1 (0.77) | HTR6L3MBTL1HTR2AHTR7 | |
| SCHEMBL13302162 | 0.81 | HTR6 (0.64) | HTR6HTR2AHTR7DRD2PPARG | |
| SCHEMBL1888939 | 0.81 | HTR6 (0.64) | HTR6HTR2AHTR7DRD2PPARG | |
| SCHEMBL4776849 | 0.80 | KDM4E (0.64) | HTR6HTR2AHTR7DRD2PPARG | |
| SCHEMBL13302225 | 0.80 | HTR6 (0.57) | HTR6HTR2AHTR7DRD2PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362066-B2 | Compounds and methods for treating protein folding disorders | TREVENTIS CORPORATION (US) | 2013-01-29 | — | — | US | disclosed |
| US-20100144821-A1 | COMPOUNDS AND METHODS FOR TREATING PROTEIN FOLDING DISORDERS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144821-A1 | COMPOUNDS AND METHODS FOR TREATING PROTEIN FOLDING DISORDERS | SNCA, MAPT, APP | HTR6 881/4885L3MBTL1 2503/4885HTR2A 849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.